Suono Bio Reports Encouraging Results From a First in Human (FiH) Study of Its Ultrasound Mediated Drug Delivery Platform
In a recent study, Suono Bio Inc. has unveiled promising findings from its first clinical trial testing the SuonoCalm™ platform. This groundbreaking study demonstrates the feasibility and safety of using ultrasound for drug delivery in the gastrointestinal tract.
The study conducted by Suono Bio showcases the safety and tolerability of ultrasound in the gastrointestinal tract, providing encouraging results for their ultrasonic platform. The findings highlight that drugs can be delivered rapidly and safely to patients by applying ultrasound locally in the GI tract. Not only does this set the stage for their clinical program, but it also paves the way for other programs, including ingestible pill formats for oral delivery of biologics.